On Wednesday, in the course of current trade, Shares of JPMorgan Chase & Co. (NYSE:JPM), gained 1.12%, and is now trading at $66.76.
JPMorgan Chase & Co., hosted its third annual Defined Contribution Advisor Summit in New York, bringing together select retirement advisors from across the country to talk about influential trends transforming the future of retirement. The forum enabled advisors to share their collective insights on how best to serve defined contribution (DC) plan sponsors and participants.
Summit sessions — counting “Improving Participant Outcomes through Innovative Plan Change”; “Fiduciary Misperceptions: Reality, Responsibility and Mitigating Risk”; and “Navigating the Ever-Changing Health Care Landscape: Implications for Employer Sponsored Retirement Benefits” — were presented to provide new insights into industry trends and developments, in addition to more information on resources and tools accessible to retirement advisors recently.
JPMorgan Chase & Co. provides various financial services worldwide. The company operates through four segments: Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, and Asset Administration.
During an Afternoon trade, Shares of Arch Coal Inc. (NYSE:ACI), dipped -0.24%, and is now trading at $0.54.
Arch Coal, stock coverage was initiated at Goldman Sachs with a “neutral” rating and a price target of 70 cents.
Analysts cited challenges counting, high leverage ratios and low returns relative to other companies, and leverage to their cautious thermal coal outlook.
“We rate shares neutral as these concerns over the last year and with the company having a market capitalization of only $100 million,” they said.
Arch Coal, Inc. produces and sells thermal and metallurgical coal from surface and underground mines located in the United States. As of December 31, 2014, it operated or contracted out the operation of 16 mines; and owned or controlled about 5.1 billion tons of proven and probable recoverable reserves.
Shares of Baxter International Inc. (NYSE:BAX), during its Wednesday’s current trading session fell -0.63%, and is now trading at $65.95, hitting its lowest level.
Baxter Ventures, the venture arm of Baxter International, declared the formation of Vitesse Biologics, LLC, (“Vitesse”). Vitesse is a unique partnership model initiated by Baxter Ventures to focus on the development of antibody and protein-based therapeutics in the areas of immunology, hematology, and oncology. Following the spin-off of Baxter BioScience as Baxalta Incorporated, anticipated to take place by mid-2015, the Vitesse relationship will be managed by the planned venture arm, Baxalta Ventures, for the new company.
The partnership model, which represents a new method of drug development, was designed to incent each partner to advance promising therapies quickly through the development process. Each partner will provide its recognized expertise to enhance the target selection, target optimization, expression and product development process. Baxter BioScience will provide global commercialization, antibody and protein development and manufacturing capabilities; Mayo Clinic researchers will execute the Phase I clinical trials; VPD will be responsible for target identification, selection of early stage drug candidates and will lead the design and execution of pre-clinical and clinical protocols.
“Delivering innovative treatments to address unmet patient needs is at the very core of everything we do and drives our ongoing R&D focus,” said Ludwig N. Hantson, Ph.D., president of Baxter BioScience. “By creating Vitesse, our business is executing on a new concept in early stage R&D by leveraging the expertise of industry-leading partners to accelerate the identification and development of novel biologic treatments that could eventually contribute to unmet patient needs while enhancing the Baxalta commercial portfolio.”
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
